In the tumor size and metastasis subgroup, patients with high ATAD2 levels had a poorer prognosis than those with low ATAD2 levels, regardless of tumor size or metastasis status (Figures S4A–S4D). This evidence concerns the gene ATAD2 and neoplasm.